157 related articles for article (PubMed ID: 33792743)
1. [Risk-adapted prostate cancer screening-update 2021].
Al-Monajjed R; Arsov C; Albers P
Urologe A; 2021 May; 60(5):592-601. PubMed ID: 33792743
[TBL] [Abstract][Full Text] [Related]
2. Adherence to a risk-adapted screening strategy for prostate cancer: First results of the PROBASE trial.
Krilaviciute A; Albers P; Lakes J; Radtke JP; Herkommer K; Gschwend J; Peters I; Kuczyk M; Koerber SA; Debus J; Kristiansen G; Schimmöller L; Antoch G; Makowski M; Wacker F; Schlemmer H; Benner A; Giesel F; Siener R; Arsov C; Hadaschik B; Becker N; Kaaks R
Int J Cancer; 2023 Mar; 152(5):854-864. PubMed ID: 36121664
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial of risk-adapted screening for prostate cancer in young men-Results of the first screening round of the PROBASE trial.
Arsov C; Albers P; Herkommer K; Gschwend J; Imkamp F; Peters I; Kuczyk M; Hadaschik B; Kristiansen G; Schimmöller L; Antoch G; Rummeny E; Wacker F; Schlemmer H; Benner A; Siener R; Kaaks R; Becker N
Int J Cancer; 2022 Jun; 150(11):1861-1869. PubMed ID: 35076933
[TBL] [Abstract][Full Text] [Related]
4. [PSA screening and molecular markers].
Lakes J; Arsov C
Urologe A; 2019 May; 58(5):486-493. PubMed ID: 30874831
[TBL] [Abstract][Full Text] [Related]
5. [Prostate cancer screening: controversies and suggested solutions].
Al-Monajjed R; Arsov C; Albers P
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2018 Dec; 61(12):1544-1550. PubMed ID: 30397721
[TBL] [Abstract][Full Text] [Related]
6. Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019.
Gandaglia G; Albers P; Abrahamsson PA; Briganti A; Catto JWF; Chapple CR; Montorsi F; Mottet N; Roobol MJ; Sønksen J; Wirth M; van Poppel H
Eur Urol; 2019 Aug; 76(2):142-150. PubMed ID: 31092338
[TBL] [Abstract][Full Text] [Related]
7. Imaging-based prostate cancer screening among BRCA mutation carriers-results from the first round of screening.
Segal N; Ber Y; Benjaminov O; Tamir S; Yakimov M; Kedar I; Rosenbaum E; Sela S; Ozalvo R; Shavit-Grievink L; Keder D; Baniel J; Margel D
Ann Oncol; 2020 Nov; 31(11):1545-1552. PubMed ID: 32958357
[TBL] [Abstract][Full Text] [Related]
8. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.
Pron G
Ont Health Technol Assess Ser; 2015; 15(10):1-64. PubMed ID: 26366236
[TBL] [Abstract][Full Text] [Related]
9. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.
; Grossman DC; Curry SJ; Owens DK; Bibbins-Domingo K; Caughey AB; Davidson KW; Doubeni CA; Ebell M; Epling JW; Kemper AR; Krist AH; Kubik M; Landefeld CS; Mangione CM; Silverstein M; Simon MA; Siu AL; Tseng CW
JAMA; 2018 May; 319(18):1901-1913. PubMed ID: 29801017
[TBL] [Abstract][Full Text] [Related]
10. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
11. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence.
Hayes JH; Barry MJ
JAMA; 2014 Mar; 311(11):1143-9. PubMed ID: 24643604
[TBL] [Abstract][Full Text] [Related]
12. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
[TBL] [Abstract][Full Text] [Related]
13. Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study.
Carlsson S; Assel M; Ulmert D; Gerdtsson A; Hugosson J; Vickers A; Lilja H
Eur Urol; 2017 Jan; 71(1):46-52. PubMed ID: 27084245
[TBL] [Abstract][Full Text] [Related]
14. [PSA screening].
Spek A; Szabados B; Roosen A; Stief C
Dtsch Med Wochenschr; 2015 Sep; 140(19):1435-7. PubMed ID: 26402179
[TBL] [Abstract][Full Text] [Related]
15. Prostate Cancer Screening and the Associated Controversy.
Tabayoyong W; Abouassaly R
Surg Clin North Am; 2015 Oct; 95(5):1023-39. PubMed ID: 26315521
[TBL] [Abstract][Full Text] [Related]
16. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Schröder FH
Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
[TBL] [Abstract][Full Text] [Related]
17. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Fenton JJ; Weyrich MS; Durbin S; Liu Y; Bang H; Melnikow J
JAMA; 2018 May; 319(18):1914-1931. PubMed ID: 29801018
[TBL] [Abstract][Full Text] [Related]
18. Baseline prostate-specific antigen testing at a young age.
Loeb S; Carter HB; Catalona WJ; Moul JW; Schroder FH
Eur Urol; 2012 Jan; 61(1):1-7. PubMed ID: 21862205
[TBL] [Abstract][Full Text] [Related]
19. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
Roobol MJ; Roobol DW; Schröder FH
Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
